Home > Companies > Abraxis BioScience
Abraxis BioScience
abraxisbio.com
Abraxis BioScience is a fully integrated biotechnology company dedicated to delivering progressive therapeutics, such as ABRAXANE, and core technologies that offer patients and medical professionals safer and more effective treatments for cancer and other critical illnesses.
Improving Sponsor Oversight of the Trial Master File at Chiesi
International Conference on Neurology and Neuro Disorders
16th International Conference on Biomedical Electronics and Devices (BIODEVICES 2023)
14th International Conference on Genetics and Genetic Disorders
10th Internationl Conference on BIOIMAGING 2023
RQ BIO LAUNCHES WITH GOAL TO TRANSFORM TREATMENT AND PREVENTION OF VIRAL INFECTIOUS DISEASES THROUGH ANTIBODY TECHNOLOGIES
RQ Bio | May 17, 2022
RQ Bio today emerges from stealth mode announcing its launch as a new UK-based biotechnology company following the completion of a successful licensing deal with AstraZeneca for RQ Bio's existing mAbs against SARS-CoV-2. The Company, which is headquartered in London, is dedicated to developing treatments and preventative therapies based on potent broad-spectrum mAbs to provide instant and long-lasting immunity for vulnerable people at risk of severe disease or death from existing, emerging a...
BLUEBIRD BIO LAUNCHES FIRST GENE THERAPY FOR BETA THALASSEMIA IN GERMANY
Labiotech | January 15, 2020
The US company bluebird bio has launched the first gene therapy for the blood disorder transfusion-dependent beta thalassemia in the EU, with a hospital in Germany becoming its first qualified treatment center. Bluebird bio's gene therapy, branded as Zynteglo, was given conditional market approval by the EU in June 2019. It was the first gene therapy approved to treat people over 12 years of age with all but the most severe form of transfusion-dependent beta thalassemia, a condition that n...
MEDGENOME TO INVESTMENT $55M LED BY LEAPFROG INVESTMENTS
Express Healthcare | April 02, 2020
The investment in MedGenome will seek to capitalise on favourable dynamics in both domestic, international markets for genetic diagnostics. MedGenome recently announced an investment of $55m led by LeapFrog Investments. Existing investors Sofina and Sequoia also participated in the round. Sam Santhosh, CEO and Founder, MedGenome said, "Genomics and personalised medicine are the future of healthcare, but emerging markets remain significantly under-penetrated. As the largest player in India ...
BEIGENE INITIATES FIRST-IN-HUMAN PHASE 1 CLINICAL TRIAL OF INVESTIGATIONAL TYK2 INHIBITOR BGB-23339
BeiGene | November 23, 2021
BeiGene a global, science-driven biotechnology company focused on developing innovative and affordable medicines, announced that the first patient has been dosed in a Phase 1 clinical trial of BGB-23339, a potent, allosteric investigational tyrosine kinase 2 (TYK2) inhibitor internally developed by BeiGene scientists. TYK2 is a member of the JAK family and functions as a critical mediator in cytokine signaling pathways implicated in multiple immune-mediated disorders, such as psor...
MEDTECH, INDUSTRIAL IMPACT
Further Discussion on Plasmids to Establish Release Specifications Using a Risk-Based Approach to Manage Supply
CELL AND GENE THERAPY, INDUSTRIAL IMPACT
Document quality control emerges as a discipline in its own right
Valorization of Starch to Biobased Materials